Grey J E, Lowe G, Bale S, Harding K G
Wound Healing Research Unit, University of Wales College of Medicine, Cardiff, UK.
J Wound Care. 1998 Jul;7(7):324-5. doi: 10.12968/jowc.1998.7.7.324.
The aim of this open, non-comparative study was to assess the potential benefit of tissue-engineered human dermis (Dermagraft) in healing long-standing, difficult-to-heal diabetic foot ulcers, and the practicality of its use in the UK. Six patients with full-thickness neuropathic diabetic foot ulcers which extended into subcutaneous tissue and had an area > 1 cm2 were included. The treatment was applied weekly for eight weeks and the patients were followed for a total of 24 weeks. Four patients completed the study, showing improvement ranging from a reduction of 26% in ulcer area to complete healing. Two patients were withdrawn after developing complications not associated with the treatment. We conclude that this tissue-engineered human dermis has a role in the treatment of diabetic foot ulcers as part of a comprehensive treatment package. A study to confirm effectiveness in a comparative trial and optimise patient selection is indicated.
这项开放性、非对照研究的目的是评估组织工程化人真皮（Dermagraft）在治疗长期难愈的糖尿病足溃疡方面的潜在益处，以及其在英国使用的实用性。纳入了6例全层神经性糖尿病足溃疡患者，溃疡已延伸至皮下组织且面积>1平方厘米。每周进行一次治疗，持续8周，对患者总共随访24周。4例患者完成了研究，溃疡面积缩小26%至完全愈合不等，显示出病情改善。2例患者在出现与治疗无关的并发症后退出研究。我们得出结论，作为综合治疗方案的一部分，这种组织工程化人真皮在糖尿病足溃疡治疗中具有一定作用。有必要开展一项对照试验以证实其有效性并优化患者选择。
